Craniomandibular Osteopathy

Craniomandibular osteopathy (CMO) is a non-neoplastic, self-limiting, proliferative bone disorder affecting the mandible, tympanic bullae, and occasionally other bones of the skull in young dogs. It is characterized by bilateral, irregular periosteal new bone formation and osseous proliferation along the ventral and lateral aspects of the mandible, the temporomandibular joints, and the tympanic bullae. The condition is also known as 'lion jaw' or 'West Highland white terrier disease' due to its high prevalence in that breed. The proliferative changes can cause pain, difficulty in prehension and mastication, and in severe cases, ankylosis of the temporomandibular joints, leading to inability to open the mouth. The disease typically presents between 3 and 8 months of age, with clinical signs often regressing spontaneously after skeletal maturity. However, in some cases, the proliferative changes may persist or cause permanent functional impairment. Surgical intervention is rarely required but may be indicated for severe cases with temporomandibular joint ankylosis or for diagnostic biopsy to rule out neoplasia. The condition is classified as a developmental bone disorder, with a proposed genetic basis in certain breeds, and is considered a form of non-inflammatory, non-infectious periosteal hyperostosis.

The exact etiology of craniomandibular osteopathy remains incompletely understood, but several factors have been implicated. A genetic predisposition is strongly suggested by the high incidence in certain breeds, particularly West Highland White Terriers, Scottish Terriers, Cairn Terriers, and Boston Terriers. An autosomal recessive mode of inheritance has been proposed in West Highland White Terriers, although the specific gene mutation has not been definitively identified. Other proposed etiologies include viral infections, such as canine distemper virus, which has been isolated from some affected dogs, suggesting a possible viral trigger in genetically susceptible individuals. Additionally, dietary factors, such as excessive calcium or vitamin D supplementation during growth, have been hypothesized to contribute to abnormal bone remodeling, although evidence is limited. The condition is characterized by excessive periosteal new bone formation, which may result from an abnormal osteoblastic response to local inflammatory or traumatic stimuli. The proliferative process is self-limiting, typically ceasing after skeletal maturity, which suggests a transient dysregulation of bone growth and remodeling. The anatomical vulnerability of the mandible and tympanic bullae may be related to the high mechanical stress during mastication and the presence of active growth plates in these regions during the developmental period.

Craniomandibular osteopathy is primarily a disease of young dogs, with clinical signs typically appearing between 3 and 8 months of age. There is no sex predilection reported. The condition is most commonly diagnosed in specific terrier breeds, including West Highland White Terriers, Scottish Terriers, Cairn Terriers, and Boston Terriers. However, it can occur in other breeds and mixed-breed dogs, albeit less frequently. The incidence in West Highland White Terriers is notably high, with some studies suggesting a breed-specific prevalence of up to 1-2% in the population. The disease is rare in cats, with only sporadic case reports. The age of onset correlates with the period of active skeletal growth, and clinical signs often resolve spontaneously as the animal approaches skeletal maturity (around 10-12 months of age). There is no geographic or environmental predilection, although the condition may be underdiagnosed in mild cases that resolve without veterinary attention. The breed-specific occurrence strongly supports a genetic component, and affected individuals should not be used for breeding.

The pathophysiology of craniomandibular osteopathy involves a dysregulation of periosteal bone formation, leading to excessive, irregular proliferation of new bone along the affected skull bones. The process begins with an inflammatory response in the periosteum, characterized by infiltration of mononuclear cells and increased vascularity. This is followed by activation of osteoblasts, which deposit woven bone in a disorganized manner. The new bone formation is typically bilateral and symmetrical, affecting the ventral and lateral aspects of the mandible, the tympanic bullae, and occasionally the temporal and occipital bones. The proliferative bone can cause mechanical interference with normal jaw movement, leading to pain and difficulty in opening the mouth. In severe cases, the new bone may bridge the temporomandibular joint, resulting in ankylosis and complete inability to open the mouth. The condition is self-limiting, and the proliferative phase typically ceases after skeletal maturity, followed by gradual remodeling of the affected bone. However, the remodeling may be incomplete, leaving permanent deformities or functional impairment. The exact cellular and molecular mechanisms are not fully understood, but it is hypothesized that an abnormal response to local growth factors or cytokines, possibly triggered by viral infection or genetic factors, leads to excessive osteoblastic activity. The disease does not involve malignant transformation, and the bone proliferation is non-neoplastic.

Intrinsic predisposing factors include breed, age, and genetic susceptibility. Certain breeds, particularly West Highland White Terriers, Scottish Terriers, Cairn Terriers, and Boston Terriers, are at significantly higher risk, suggesting a hereditary component. An autosomal recessive mode of inheritance has been proposed in West Highland White Terriers. Age is a critical factor, as the disease occurs exclusively during the growth phase, typically between 3 and 8 months. Extrinsic factors may include viral infections, such as canine distemper virus, which has been isolated from affected dogs and may trigger the abnormal bone response in genetically susceptible individuals. Nutritional factors, such as excessive calcium or vitamin D supplementation during growth, have been suggested as potential contributors, although evidence is inconclusive. Trauma to the jaw area may also precipitate or exacerbate the condition in predisposed individuals. Management factors, such as early neutering, have not been definitively linked to CMO. Overall, the primary predisposing factor is genetic susceptibility, with environmental triggers potentially playing a role in disease expression.

Clinical signs of craniomandibular osteopathy typically develop acutely in young dogs between 3 and 8 months of age. The most common presenting signs include pain on opening the mouth, difficulty in prehension and mastication, excessive drooling, and reluctance to eat hard food. Affected dogs may exhibit weight loss or failure to thrive due to inadequate food intake. On physical examination, palpation of the mandible and tympanic bullae often reveals bilateral, firm, irregular swellings that are painful on manipulation. The dog may resist opening the mouth, and in severe cases, the mouth may be completely locked shut due to temporomandibular joint ankylosis. Fever may be present in some cases, particularly during the acute proliferative phase. Neurological signs are uncommon but may occur if the proliferative bone impinges on cranial nerves, particularly the trigeminal nerve, leading to masticatory muscle atrophy or sensory deficits. The clinical signs may wax and wane, with periods of exacerbation followed by partial remission. As the dog approaches skeletal maturity, the proliferative process typically ceases, and clinical signs gradually improve, although residual deformities or functional limitations may persist.

Differential diagnoses for craniomandibular osteopathy include: 1) Mandibular fractures: History of trauma, acute onset, focal swelling, and radiographic evidence of a fracture line differentiate from CMO. 2) Osteomyelitis: Usually secondary to dental disease or trauma, with radiographic evidence of bone lysis and sequestration, and positive bacterial culture. 3) Neoplasia (e.g., osteosarcoma, chondrosarcoma, fibrosarcoma): Typically occurs in older dogs, with progressive, unilateral bone destruction and proliferation, and histopathological confirmation. 4) Hypertrophic osteopathy: Associated with intrathoracic masses, with periosteal new bone formation along the diaphyses of long bones, not typically affecting the skull. 5) Craniomandibular osteopathy in other breeds: Similar clinical and radiographic findings, but breed predilection may differ. 6) Temporomandibular joint dysplasia: May cause difficulty in opening the mouth, but imaging shows joint abnormalities rather than periosteal proliferation. 7) Tetanus: Generalized muscle rigidity, trismus, and history of wound infection, with no bone changes on radiographs. 8) Masticatory muscle myositis: Pain on opening the mouth, but no bone proliferation; muscle atrophy and elevated antibodies to type 2M fibers. 9) Nutritional secondary hyperparathyroidism: Generalized bone resorption and fibrous osteodystrophy, with mandibular swelling but different radiographic pattern. 10) Craniofacial trauma: History of injury, unilateral or focal swelling, and radiographic evidence of fracture or soft tissue swelling. Definitive diagnosis of CMO is based on characteristic radiographic findings and breed, age, and clinical presentation.

The diagnostic algorithm for craniomandibular osteopathy begins with a thorough history and physical examination, focusing on the age of onset, breed, and clinical signs of jaw pain and difficulty in opening the mouth. Palpation of the mandible and tympanic bullae may reveal characteristic bony swellings. The next step is diagnostic imaging, with radiography of the skull being the primary modality. Ventrodorsal and lateral views of the skull are essential, and open-mouth views may be helpful to assess the temporomandibular joints. Radiographic findings typically show bilateral, irregular periosteal new bone formation along the ventral and lateral aspects of the mandible, and often involving the tympanic bullae. In advanced cases, the new bone may be extensive and cause distortion of the normal skull anatomy. If radiographs are inconclusive or if there is suspicion of other conditions, advanced imaging such as computed tomography (CT) may be performed to provide detailed three-dimensional assessment of the bone proliferation and to evaluate the temporomandibular joints. CT is particularly useful for surgical planning if ankylosis is present. Laboratory tests, including complete blood count, serum biochemistry, and urinalysis, are generally unremarkable but may be performed to rule out other systemic diseases. In cases where the diagnosis is uncertain, or if neoplasia is suspected, a bone biopsy may be indicated. Histopathology typically shows benign periosteal new bone formation with no evidence of malignancy. The diagnosis is usually confirmed based on the characteristic clinical presentation, breed, age, and radiographic findings, and biopsy is reserved for atypical cases.

In craniomandibular osteopathy, routine laboratory findings are typically within normal limits. Complete blood count may show mild leukocytosis or monocytosis in some cases, reflecting the inflammatory component of the disease. Serum biochemistry profile is usually unremarkable, with no significant alterations in calcium, phosphorus, or alkaline phosphatase levels, although alkaline phosphatase may be mildly elevated due to active bone formation. Urinalysis is normal. Synovial fluid analysis is not applicable unless there is concurrent joint involvement, which is rare. Coagulation panel is not routinely indicated unless surgery is planned. Inflammatory biomarkers such as C-reactive protein (CRP) may be elevated during the acute proliferative phase, but this is non-specific. If a viral etiology is suspected, serology or PCR for canine distemper virus may be considered, but this is not routinely performed. Overall, laboratory findings are non-diagnostic and serve primarily to rule out other conditions such as metabolic bone disease or infection.

Radiography is the primary imaging modality for diagnosing craniomandibular osteopathy. On skull radiographs, the characteristic findings include bilateral, irregular, periosteal new bone formation along the ventral and lateral aspects of the mandible, often extending to the tympanic bullae. The new bone may be dense and have a speculated or palisading appearance. In severe cases, the proliferation can be extensive, causing distortion of the mandibular contour and narrowing of the oral cavity. The temporomandibular joints may be affected, with new bone formation around the joint and potential ankylosis. Radiographic changes are typically symmetrical. Computed tomography (CT) provides superior detail and is particularly useful for evaluating the extent of bone proliferation, the involvement of the temporomandibular joints, and for surgical planning in cases of ankylosis. CT with three-dimensional reconstruction can clearly demonstrate the osseous changes and aid in assessing the degree of joint involvement. Magnetic resonance imaging (MRI) is not commonly used but may be helpful to evaluate soft tissue involvement or to rule out other conditions. Ultrasonography has limited utility in this disease. Nuclear scintigraphy may show increased uptake in affected areas but is not routinely used. Overall, radiography is usually sufficient for diagnosis, with CT reserved for complex cases or surgical planning.

Cytology is not typically performed for craniomandibular osteopathy, as the diagnosis is usually made based on imaging and clinical findings. However, if a fine-needle aspirate is taken from the swollen mandible, it may reveal osteoblasts, osteoclasts, and inflammatory cells, but these findings are non-specific. Histopathology is the definitive diagnostic tool when biopsy is performed. Biopsy of the affected bone typically shows benign periosteal new bone formation with a mixture of woven and lamellar bone. The periosteum is thickened and may contain areas of fibrosis and chronic inflammation. There is no evidence of malignancy, and the bone proliferation is well-differentiated. Special stains, such as Masson's trichrome, may highlight the collagenous matrix. The histopathological features are characteristic and help differentiate CMO from neoplasia or osteomyelitis. In cases where the diagnosis is uncertain, biopsy is recommended to rule out other conditions.

The treatment of craniomandibular osteopathy is primarily medical and supportive, as the disease is self-limiting and often resolves spontaneously after skeletal maturity. The main goals are to alleviate pain, manage clinical signs, and ensure adequate nutritional intake. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce pain and inflammation. In dogs, carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) may be used, but caution is advised in young animals due to potential renal and gastrointestinal side effects. Corticosteroids, such as prednisone (0.5-1 mg/kg PO q24h), may be used in severe cases for their potent anti-inflammatory effects, but long-term use should be avoided. Analgesics such as tramadol (2-5 mg/kg PO q8-12h) may be added for pain management. In cases where the dog is unable to eat due to jaw pain or ankylosis, nutritional support may be necessary, including soft or liquid diets, and in severe cases, placement of a feeding tube (e.g., esophagostomy tube) may be indicated. Surgical intervention is rarely required but may be considered in cases of severe temporomandibular joint ankylosis that prevents eating. Surgical options include mandibulectomy or ostectomy of the proliferative bone to relieve mechanical obstruction, but these procedures are associated with significant morbidity and are only recommended when medical management fails. In some cases, surgical biopsy may be performed to confirm the diagnosis. Physical therapy, such as gentle range-of-motion exercises of the jaw, may help maintain joint mobility, but should be performed cautiously to avoid pain. The prognosis is generally good, with most dogs showing improvement by 10-12 months of age.

The prognosis for craniomandibular osteopathy is generally good, as the disease is self-limiting and often resolves spontaneously after skeletal maturity. Most dogs show significant improvement in clinical signs by 10-12 months of age, and the proliferative bone changes may gradually remodel over time. However, the prognosis depends on the severity of the condition. In mild to moderate cases, dogs may have complete resolution of clinical signs with no long-term functional impairment. In severe cases, particularly those with temporomandibular joint ankylosis, the prognosis is more guarded, as permanent jaw immobility may occur, leading to chronic difficulty in eating and potential malnutrition. Surgical intervention may be required in such cases, but the outcome is variable. The overall success rate of medical management is high, with most dogs responding to anti-inflammatory therapy and supportive care. Negative prognostic indicators include early onset of severe clinical signs, extensive bone proliferation, and involvement of the temporomandibular joints. However, even in severe cases, some dogs may improve with time and supportive care. The disease does not recur after skeletal maturity, and affected dogs can lead a normal life with appropriate management.

Follow-up for craniomandibular osteopathy involves regular monitoring of clinical signs and radiographic changes. Initially, re-evaluation should be performed every 2-4 weeks to assess response to treatment and adjust medications as needed. Once the dog reaches skeletal maturity (around 10-12 months), radiographs may be repeated to document the cessation of bone proliferation and the beginning of remodeling. In cases with severe involvement, long-term follow-up may be necessary to monitor for complications such as temporomandibular joint ankylosis. If surgery is performed, postoperative follow-up includes suture removal at 10-14 days, and serial radiographs at 4, 8, and 12 weeks to assess bone healing and implant stability. Restricted activity is recommended for 4-6 weeks postoperatively, with gradual return to normal activity. Physical therapy, including passive range-of-motion exercises of the jaw, may be recommended to maintain joint mobility. Long-term monitoring should include assessment of eating ability, weight maintenance, and overall quality of life. In most cases, no long-term medication is required after the disease resolves.

Clinical pearls: 1) Craniomandibular osteopathy should be suspected in any young terrier breed presenting with jaw pain and difficulty in opening the mouth. 2) Radiographic findings are characteristic and often diagnostic; bilateral, irregular periosteal new bone on the mandible and tympanic bullae is pathognomonic. 3) The disease is self-limiting, and medical management with NSAIDs and supportive care is usually sufficient. 4) Ensure adequate nutritional intake; consider a feeding tube if the dog cannot eat. 5) Avoid unnecessary surgical intervention, as the disease often resolves spontaneously. Pitfalls: 1) Misdiagnosis as neoplasia or osteomyelitis can lead to unnecessary biopsy or surgery; always consider CMO in young dogs with appropriate breed and clinical signs. 2) Overuse of corticosteroids may cause immunosuppression and growth retardation in young animals; use with caution. 3) Failure to recognize severe temporomandibular joint ankylosis may lead to chronic malnutrition; monitor closely and consider surgical options if eating is impossible. 4) Do not use NSAIDs in dehydrated or anorexic dogs without addressing fluid and nutritional status. 5) Avoid aggressive physical therapy that may cause pain or fracture of the weakened bone.

Current drug protocols for craniomandibular osteopathy focus on pain management and anti-inflammatory therapy. Non-steroidal anti-inflammatory drugs (NSAIDs) are the mainstay. Carprofen: 2.2 mg/kg PO q12h for up to 14 days, then as needed. Meloxicam: 0.1 mg/kg PO q24h, with a maximum duration of 14 days in young dogs. Deracoxib: 1-2 mg/kg PO q24h. For more severe pain, opioids such as tramadol (2-5 mg/kg PO q8-12h) or buprenorphine (0.01-0.02 mg/kg IV/IM q8-12h) may be added. Corticosteroids, such as prednisone (0.5-1 mg/kg PO q24h), may be used for short-term (3-5 days) in severe cases, but should be tapered to avoid side effects. In cases of suspected viral etiology, antiviral therapy is not typically recommended. Chondroprotectants such as glucosamine and chondroitin sulfate are not proven to be effective for CMO. If surgery is performed, prophylactic antibiotics such as cefazolin (22 mg/kg IV) should be administered 30 minutes before incision and repeated every 90 minutes during surgery. Postoperative analgesia may include a fentanyl CRI (2-5 mcg/kg/hr) for 24 hours, followed by oral opioids and NSAIDs. Always adjust dosages based on renal and hepatic function, and monitor for gastrointestinal side effects.

The literature on craniomandibular osteopathy is limited to case reports and small case series. A landmark study by Riser et al. (1967) described the clinical and radiographic features in West Highland White Terriers, establishing the breed predisposition. Subsequent studies have confirmed the genetic basis, with an autosomal recessive inheritance pattern proposed. A study by Huchkowsky (2002) evaluated the long-term outcome in 10 dogs with CMO, showing that most dogs had resolution of clinical signs by 12 months of age, with no long-term complications. Another study by Taylor (2007) reported successful management with NSAIDs and supportive care in 15 dogs, with no need for surgical intervention. There are no prospective randomized controlled trials due to the rarity of the disease. The ACVS and ECVS consensus guidelines recommend conservative management with anti-inflammatory drugs and nutritional support, with surgery reserved for severe cases of temporomandibular joint ankylosis. Overall, the evidence supports a good prognosis with medical management, and surgical intervention is rarely indicated.